The Women’s Health Clinic (TWHC) agrees with U.S. Food and Drug Administration
(FDA) warning – “Vaginal Rejuvenation” and potential health risk
- Vaginal rejuvenation procedures are becoming more popular to relieve painful sex, dryness and stress incontinence. There is an inherent confusion in relation to the medical nature of the treatment and as a result the Regulatory System is being taken advantage of by non-medical aesthetic professionals
- The FDA issued a stern warning the industry highlighting the non-compliance and the very serious nature of the risk involved in such procedure.
- FDA Commissioner Scott Gottlieb said the agency was “deeply concerned women are being harmed.”
- The Women’s Health Clinic welcomes the FDA report and requests UK Authority to bring in Legislation to introduce basic safety net in the system in order that these treatments can only be performed by qualified medical professionals with proper knowledge of the technology
- TWHC however identified serious weaknesses in the FDA report as it failed to address the subject with due care and sensitivity it deserves.
- Coincidentally British Menopause Society released a consensus statement within 24 hours of the FDA report advocating the use of LVR for improvement in sexual response.
By: Emma Louise RN | Aly Dilks RN | Mr Vivek Nama Consultant Gynaecologist MBBS, MD, DNB, MRes, MRCOG
Referencing – Laser Vaginal Rejuvenation (LVR) with CO2 lasers (Nu-V)